Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

A Pharmacist-Led Collaborative Care Model for Cardiometabolic Risk Reduction: A Case Study

A Pharmacist-Led Collaborative Care Model for Cardiometabolic Risk Reduction: A Case Study A Pharmacist-Led Collaborative Care Model for Cardiometabolic Risk Reduction: A Case Study SHAWN R. SMITH, PHARMD MICHAEL S. MURCHIE, MD CHRISTIAN W. RUIZ, PHARMD STEVE H. CROSSMAN, MD SALIHAH ALI, PHARMD JOHN D. BUCHEIT, PHARMD, CDCES, BCACP CAROLINE J. KIM, PHARMD Type 2 diabetes is a chronic disease aff ecting morbidity and mortality in this population. approximately 30.3 million people in the United The glucagon-like peptide-1 (GLP-1) States. People with diabetes (PWD) often have receptor agonists and the sodium-glucose cormorbid conditions such as hypertension, co-transporter-2 (SGLT-2) inhibitors improve hyperlipidemia, and kidney disease, which cardiovascular outcomes in people with type 3-11 contribute to the development of atherosclerotic 2 diabetes. Because GLP-1 receptor agonists cardiovascular disease (ASCVD) and heart failure. and SGLT-2 inhibitors confer both glycemic and Given that the most common cause of death cardiovascular benefi ts, they are recommended for PWD is due to macrovascular complications, by the American Diabetes Association (ADA) eff orts are warranted to decrease cardiovascular as fi rst-line agents for PWD with ASCVD, heart 16 // ADCES IN PRACTICE // May 2021 failure, and chronic kidney disease and in PWD at Case Presentation increased risk of ASCVD. However, these agents A 49-year-old uninsured African American http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png ADCES in Practice SAGE

A Pharmacist-Led Collaborative Care Model for Cardiometabolic Risk Reduction: A Case Study

Loading next page...
 
/lp/sage/a-pharmacist-led-collaborative-care-model-for-cardiometabolic-risk-aZGAmuYMzN
Publisher
SAGE
Copyright
© 2021 by the American Association of Diabetes Educators
ISSN
2633-559X
eISSN
2633-5603
DOI
10.1177/2633559x21994855
Publisher site
See Article on Publisher Site

Abstract

A Pharmacist-Led Collaborative Care Model for Cardiometabolic Risk Reduction: A Case Study SHAWN R. SMITH, PHARMD MICHAEL S. MURCHIE, MD CHRISTIAN W. RUIZ, PHARMD STEVE H. CROSSMAN, MD SALIHAH ALI, PHARMD JOHN D. BUCHEIT, PHARMD, CDCES, BCACP CAROLINE J. KIM, PHARMD Type 2 diabetes is a chronic disease aff ecting morbidity and mortality in this population. approximately 30.3 million people in the United The glucagon-like peptide-1 (GLP-1) States. People with diabetes (PWD) often have receptor agonists and the sodium-glucose cormorbid conditions such as hypertension, co-transporter-2 (SGLT-2) inhibitors improve hyperlipidemia, and kidney disease, which cardiovascular outcomes in people with type 3-11 contribute to the development of atherosclerotic 2 diabetes. Because GLP-1 receptor agonists cardiovascular disease (ASCVD) and heart failure. and SGLT-2 inhibitors confer both glycemic and Given that the most common cause of death cardiovascular benefi ts, they are recommended for PWD is due to macrovascular complications, by the American Diabetes Association (ADA) eff orts are warranted to decrease cardiovascular as fi rst-line agents for PWD with ASCVD, heart 16 // ADCES IN PRACTICE // May 2021 failure, and chronic kidney disease and in PWD at Case Presentation increased risk of ASCVD. However, these agents A 49-year-old uninsured African American

Journal

ADCES in PracticeSAGE

Published: May 1, 2021

There are no references for this article.